Bacteriophage as a novel therapeutic approach for killing multidrug-resistant Escherichia coli ST131 clone

The emergence of the multidrug-resistant (MDR) <i>Escherichia coli</i> ST131 clone has significantly impacted public health. With traditional antibiotics becoming less effective against MDR bacteria, there is an urgent need for alternative treatment options. This study aimed to isolate and characterize four lytic phages (EC.W2-1, EC.W2-6, EC.W13-3, and EC.W14-3) from hospital sewage water and determine their effectiveness against the ST131 clone. These phages demonstrated a broad host range, effectively lysing 94.4% of highly pathogenic <i>E. coli</i> ST131 isolates. Morphological observations and phylogenetic analysis indicate that EC.W2-1, and EC.W13-3 belong to the <i>Tequatrovirus</i> genus in the <i>Straboviridae</i> family, while EC.W2-6 and EC.W14-3 are part of the <i>Kuravirus</i> genus in the <i>Podoviridae</i> family. Phages remained stable at pH 2-10 for 4 h and below 80°C for 1 h. These four phages showed <i>in vitro</i> bacterial lytic activity at various MOIs (0.1-0.001). The one-step growth curve of phages exhibited a short latent period of approximately 10-20 min and a moderate burst size of 50-80 (pfu/cell). Phages' genome size ranged from 46,325-113,909 bp, with G + C content of 35.1 -38.3%. No virulence or drug resistance genes were found, which enhanced their safety profile. <i>In vivo</i>, EC.W2-6 and EC.W13.3, along with their cocktail, fully protected against the ESBL-producing <i>E. coli</i> ST131 infection model <i>in vivo</i>. Combining these phages and a 3-day repeated single phage, EC.W13-3 significantly enhanced the survival rate of <i>E. coli</i> ST131 infected mice at low MOI (0.01-0.001). The <i>in vivo</i> effectiveness of the isolated phages and the EC.W2-6 and EC.W14-3 cocktail in highly reducing bacterial load CFU/g in multiple organs strongly supports their potential efficacy. Based on <i>in vivo</i>, <i>in vitro</i>, and genomic analyses, phages have been proposed as novel and suitable candidates for killing the pandemic ST131 clone.

Authors

Institutions

Publication Details

Journal
Frontiers in Microbiology
Published
2024-12-12
DOI
https://doi.org/10.3389/fmicb.2024.1455710
Citations
7
Primary Topic
Bacteriophages and microbial interactions
Type
article
Field-Weighted Citation Impact
3.21

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Bacteriophage as a novel therapeutic approach for killing multidrug-resistant Escherichia coli ST131 clone

Shukho Kim, Jung Min Kim, Md Shamsuzzaman
7 citations
Frontiers in Microbiology
Bacteriophages and microbial interactions
3.21
article

Bacteriophage as a novel therapeutic approach for killing multidrug-resistant Escherichia coli ST131 clone

Shukho Kim, Jung Min Kim, Md Shamsuzzaman
article en
7 citations

Abstract

The emergence of the multidrug-resistant (MDR) <i>Escherichia coli</i> ST131 clone has significantly impacted public health. With traditional antibiotics becoming less effective against MDR bacteria, there is an urgent need for alternative treatment options. This study aimed to isolate and characterize four lytic phages (EC.W2-1, EC.W2-6, EC.W13-3, and EC.W14-3) from hospital sewage water and determine their effectiveness against the ST131 clone. These phages demonstrated a broad host range, effectively lysing 94.4% of highly pathogenic <i>E. coli</i> ST131 isolates. Morphological observations and phylogenetic analysis indicate that EC.W2-1, and EC.W13-3 belong to the <i>Tequatrovirus</i> genus in the <i>Straboviridae</i> family, while EC.W2-6 and EC.W14-3 are part of the <i>Kuravirus</i> genus in the <i>Podoviridae</i> family. Phages remained stable at pH 2-10 for 4 h and below 80°C for 1 h. These four phages showed <i>in vitro</i> bacterial lytic activity at various MOIs (0.1-0.001). The one-step growth curve of phages exhibited a short latent period of approximately 10-20 min and a moderate burst size of 50-80 (pfu/cell). Phages' genome size ranged from 46,325-113,909 bp, with G + C content of 35.1 -38.3%. No virulence or drug resistance genes were found, which enhanced their safety profile. <i>In vivo</i>, EC.W2-6 and EC.W13.3, along with their cocktail, fully protected against the ESBL-producing <i>E. coli</i> ST131 infection model <i>in vivo</i>. Combining these phages and a 3-day repeated single phage, EC.W13-3 significantly enhanced the survival rate of <i>E. coli</i> ST131 infected mice at low MOI (0.01-0.001). The <i>in vivo</i> effectiveness of the isolated phages and the EC.W2-6 and EC.W14-3 cocktail in highly reducing bacterial load CFU/g in multiple organs strongly supports their potential efficacy. Based on <i>in vivo</i>, <i>in vitro</i>, and genomic analyses, phages have been proposed as novel and suitable candidates for killing the pandemic ST131 clone.

Frontiers in MicrobiologyVol. 15
Kyungpook National University (KR)
Korea Disease Control and Prevention Agency
Clean water and sanitation
Openalex Percentile: Top 8%
Bacteriophages and microbial interactions
3.21
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.